scientific programme - eau20v virtual moses 2.0 – new levels … · 2020. 11. 18. · moses 2.0...

MOSES 2.0 – New levels of versatility and precisionIndustry Session Lumenis

Sunday 26 July17:45 - 18:45

Location Virtual room 2

Chair B. Somani, Southampton (GB)

17:45 - 17:46 IntroductionB. Somani, Southampton (GB)

17:46 - 18:06 MOSES 2.0 – Improving the gold standard for laser lithotripsyK. Ghani, Ann Arbor (US)

18:06 - 18:23 MOSES 2.0 for BPH treatmentsA.E. Krambeck, Indianapolis (US)

18:23 - 18:33 MOSES for AEEP: How does it compare to other energy sourcesT. Aho, Cambridge (GB)

18:33 - 18:45 Live discussion and Q&AT. Aho, Cambridge (GB)K. Ghani, Ann Arbor (US)A.E. Krambeck, Indianapolis (US)B. Somani, Southampton (GB)

Scientific Programme - EAU20V Virtual

1

New horizons in metastatic prostate cancerIndustry Session by Sanofi Genzyme

Saturday 25 July17:45 - 18:45


Chair N. Mottet, Saint-Étienne (FR)

17:45 - 17:47 Welcome and introductionN. Mottet, Saint-Étienne (FR)

17:47 - 18:01 Targeting prostate cancer heterogeneity in the right wayR.J. Van Soest, Rotterdam (NL)

18:01 - 18:15 Managing metastatic hormone-sensitive disease in daily practiceA. Birtle, Preston (GB)

18:15 - 18:29 Metastatic castration-resistant prostate cancer – New learnings and perspectivesR. De Wit, Rotterdam (NL)

18:29 - 18:43 2020 EAU guidelines for the management of metastatic diseaseN. Mottet, Saint-Étienne (FR)

18:43 - 18:45 Closing remarksN. Mottet, Saint-Étienne (FR)


2

Da Vinci for partial nephrectomy: Tips on technique and apathway for day surgeryIndustry Session by Intuitive

Friday 24 July17:45 - 18:45


Chair B.J. Challacombe, London (GB)

17:45 - 17:48 IntroductionB.J. Challacombe, London (GB)

17:48 - 18:13 Robotic-assisted partial nephrectomy with da Vinci – Inspirations to refinesurgical techniquesG. Schön, Munich (DE)

18:13 - 18:38 The pathway to day-surgery for robotic-assisted partial nephrectomyJ-C. Bernhard, Bordeaux (FR)

18:38 - 18:45 DiscussionJ-C. Bernhard, Bordeaux (FR)B.J. Challacombe, London (GB)G. Schön, Munich (DE)


3

Navigating the complex evolving treatment landscape inmetastatic urothelial carcinomaIndustry Session by Astellas Pharma Europe

Thursday 23 July17:45 - 18:45


Chair W.R. Gerritsen, Nijmegen (NL)This is a non-promotional symposium intended for Healthcare Professionals with aninterest in bladder cancer, developed by Astellas.

The content of this symposium is intended for healthcare professionals only; Allcontent is aligned with local regulatory guidance.

Learning objectives• Raise awareness of unmet needs in the current treatment of metastatic urothelial

carcinoma (mUC)• Demonstrate the importance of effective management of mUC in prolonging and

improving patients’ lives• Discuss future goals in management of mUC, as indicated by an update of

development studies

17:45 - 17:51 All aboard: Management of mUC during the COVID-19 pandemicW.R. Gerritsen, Nijmegen (NL)

17:51 - 18:05 Mapping our route: Understanding patient wants and needs in mUCM. De Santis, Berlin (DE)

18:05 - 18:19 Bridging the gap: Effective management of mUC in an evolving treatmentlandscapeT. Powles, London (GB)

18:19 - 18:33 Charting our next course: What’s on the horizon in mUC?A.S. Merseburger, Lübeck (DE)

18:33 - 18:45 Panel discussion and closeModerator W.R. Gerritsen, Nijmegen (NL)Panel M. De Santis, Berlin (DE)

A.S. Merseburger, Lübeck (DE)T. Powles, London (GB)


4

Tackling the gender divide in OABIndustry Session by Astellas Pharma Europe

Wednesday 22 July17:45 - 18:45


Chair P. Van Kerrebroeck, Maastricht (NL)This symposium is fully sponsored and supported by Astellas Pharma Europe,including speaker honoraria and production of materials, and may includepromotional messages related to Astellas products.

The content of this symposium is intended for healthcare professionals only; allcontent is aligned with local regulatory guidance.

17:45 - 17:50 Live introductionP. Van Kerrebroeck, Maastricht (NL)

17:50 - 18:05 The complexities of OAB in menD. Elterman, Toronto (CA)

18:05 - 18:20 Tackling OAB: Diving into the dataS. Foley, Reading (GB)

18:20 - 18:35 Translating OAB clinical trial data into practiceS.A. Arlandis, Valencia (ES)

18:35 - 18:45 Live questions and answers session and close of meetingS.A. Arlandis, Valencia (ES)D. Elterman, Toronto (CA)S. Foley, Reading (GB)P. Van Kerrebroeck, Maastricht (NL)


5

Master class in bladder cancer: Practical solutions to commonscenarios in NMIBCIndustry Session by Medac GmbH

Tuesday 21 July17:45 - 18:45


Chair A.M. Kamat, Houston (US)

17:45 - 17:48 IntroductionA.M. Kamat, Houston (US)

17:48 - 17:53 Common problem 1: Strategies to optimize the use of BCG during times ofshortageR.J. Buckley, Toronto (CA)

17:53 - 18:06 Case based debate Intermediate risk NMIBC: What is the best management?

17:53 - 17:55 Case presentationA.M. Kamat, Houston (US)

17:55 - 17:59 Intravesical therapyR.J. Buckley, Toronto (CA)

17:59 - 18:03 Active surveillanceP. Gontero, Turin (IT)

18:03 - 18:06 Discussion

18:06 - 18:19 Case based debate High risk bladder cancer (T1HG): Is repeat resectionmandatory before deciding treatment options?


18:08 - 18:12 No, reTUR is overusedP. Gontero, Turin (IT)

18:12 - 18:16 Yes, reTUR is mandatoryM.J. Ribal Caparros, Barcelona (ES)


18:19 - 18:32 Case based debate Is it time to use systemic IO therapy for BCG unresponsivedisease?


18:21 - 18:25 Yes, evidence is sufficientM.J. Ribal Caparros, Barcelona (ES)

18:25 - 18:29 No, we have other optionsA. Stenzl, Tübingen (DE)


18:32 - 18:39 Common problem 2: Medical management of UTUC – What’s new in 2020?A. Stenzl, Tübingen (DE)

18:39 - 18:44 ConclusionA.M. Kamat, Houston (US)


6

Improving the management of recurrent cystitis in clinicalpractice: Can we do more?Industry Session by OM Pharma

Monday 20 July17:45 - 18:45


Chair F.M.E. Wagenlehner, Giessen (DE)A Vifor Pharma Group company

17:45 - 17:50 Welcome and introduction

17:50 - 18:05 Disease burden of recurrent cystitis: The importance of prompt diagnosis and riskidentificationT. Cai, Trento (IT)

18:05 - 18:20 State of the art in the management of recurrent cystitisG. Bonkat, Basel (CH)

18:20 - 18:35 The place of immunotherapy in the management of recurrent cystitis: An attractiveoptionF.M.E. Wagenlehner, Giessen (DE)

18:35 - 18:45 Questions and answers


7

The big debate: How to adapt to a changing landscape forpatients with metastatic hormone-sensitive prostate cancerIndustry Session by Astellas Pharma Europe - Endorsed by APCCC

Sunday 19 July15:10 - 16:10


Chair R.J.A. Van Moorselaar, Amsterdam (NL)This is a non-promotional symposium intended for Healthcare Professionals with aninterest in prostate cancer, developed by Astellas.

The content of this symposium is intended for healthcare professionals only; Allcontent is aligned with local regulatory guidance.

Learning objectives1. Inform on current recommended therapies for patients with mHSPC2. Discuss areas of treatment where consensus is not always achieve3. Highlight potential future diagnostic techniques for mHSPC

15:10 - 15:12 Welcome and introductionR.J.A. Van Moorselaar, Amsterdam (NL)

15:12 - 15:26 Making sense of a rapidly changing therapy areaA. Heidenreich, Cologne (DE)

15:26 - 15:40 A controversial climateJ. O'Sullivan, Belfast (GB)

15:40 - 15:54 Panel discussionPanel G. Attard, Sutton (GB)

J. O'Sullivan, Belfast (GB)R.J.A. Van Moorselaar, Amsterdam (NL)

15:54 - 16:08 Diagnosis of metastatic hormone-sensitive prostate cancer: What does the futurehold?G. Attard, Sutton (GB)

16:08 - 16:10 Summary and closeR.J.A. Van Moorselaar, Amsterdam (NL)


8

Recent advances in the treatment landscape for the patient with BCGunresponsive NMIBCIndustry Session by Medscape supported by an independent educational grant from Ferring

Saturday 18 July15:00 - 16:00


Chair S. Shariat, Vienna (AT)

15:00 - 15:10 Introduction and case presentationS. Shariat, Vienna (AT)

15:10 - 15:20 Who is the patient with BCG unresponsive NMIBC?A.M. Kamat, Houston (US)

15:20 - 15:40 Clinical trial updates for the BCG unresponsive patientM. Babjuk, Prague (CZ)

15:40 - 15:50 The BCG unresponsive patient: A patient caseJ. Palou, Barcelona (ES)

15:50 - 16:00 Panel discussion and questions and answersM. Babjuk, Prague (CZ)A.M. Kamat, Houston (US)J. Palou, Barcelona (ES)S. Shariat, Vienna (AT)

AdjournS. Shariat, Vienna (AT)


9

Current scientific questions influencing patient management inadvanced prostate cancerIndustry Session by Janssen

Friday 17 July14:30 - 15:30


Chairs L-M. Krabbe, Münster (DE)B. Tombal, Brussels (BE)

Learning objectivesAfter joining this meeting, participants should be able to:

• Describe the clinical benefits of earlier treatment of patients with metastatichormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) and the consequences of diseaseprogression

• Discuss the impact of new data on treatment and management decisions forindividual patients with mHSPC and nmCRPC

14:30 - 14:35 Welcome and introductionB. Tombal, Brussels (BE)

14:35 - 14:41 How do the big scientific questions in advanced prostate cancer shape clinicaldecision making?A. De La Taille, Créteil (FR)B.A. Hadaschik, Essen (DE)L-M. Krabbe, Münster (DE)B. Tombal, Brussels (BE)J. Walz, Marseille (FR)

14:41 - 15:01 Rethinking mHSPC - What do we need to debate?A. De La Taille, Créteil (FR)B.A. Hadaschik, Essen (DE)L-M. Krabbe, Münster (DE)B. Tombal, Brussels (BE)J. Walz, Marseille (FR)

15:01 - 15:15 nmCRPC - A disease under discussionA. De La Taille, Créteil (FR)B.A. Hadaschik, Essen (DE)L-M. Krabbe, Münster (DE)B. Tombal, Brussels (BE)J. Walz, Marseille (FR)

15:15 - 15:29 Finding answers in the management of patients with advanced prostate cancerA. De La Taille, Créteil (FR)B.A. Hadaschik, Essen (DE)L-M. Krabbe, Münster (DE)B. Tombal, Brussels (BE)J. Walz, Marseille (FR)

15:29 - 15:30 Pressing thoughts and questionsA. De La Taille, Créteil (FR)B.A. Hadaschik, Essen (DE)L-M. Krabbe, Münster (DE)B. Tombal, Brussels (BE)J. Walz, Marseille (FR)


10

scientific programme - eau20v virtual moses 2.0 – new levels … · 2020. 11. 18. · moses 2.0...

Documents